Cullinan Therapeutics (CGEM) Stock
Small biotech company focused on cancer treatments. Here's the price, business snapshot, and what's worth knowing about Cullinan Therapeutics in July 2026.
Cullinan Oncology Inc (CGEM) is a small-cap biotechnology company focused on developing targeted oncology therapies. The company advances a pipeline across multiple modalities aimed at treating various cancers; as an investor you should expect an emphasis on research and clinical development rather than recurring revenue. With a market capitalisation of around $500.95M, Cullinan sits in the early-to-mid stage of commercialisation life cycles for many biotech firms. Key considerations include the binary nature of clinical trial outcomes, regulatory review timelines, and the potential need for additional financing, which can dilute existing shareholders. The stock can be volatile and is generally suited to investors who can tolerate significant short-term swings and understand biotech development risks. This summary is for educational purposes only and does not constitute personal investment advice; always consider seeking independent financial advice and review company filings before investing.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Cullinan Therapeutics stock, expecting significant price growth ahead.
Financial Health
Cullen Therapeutics shows solid cash flow and book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CGEM
Precision Oncology Stocks: Could This Theme Gain Momentum?
Revolution Medicines recently reported stellar Phase 3 trial results for its pancreatic cancer drug, sending its stock soaring and validating novel targeted therapies. This breakthrough creates a compelling investment opportunity across the broader oncology sector, particularly for biotechnology firms specializing in genetic mutations and precision medicine.
Published: 14 April 2026
Explore BasketOncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketPharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketOncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketOncology Stocks: Could Combination Therapies Drive Growth?
Astellas and Pfizer's successful trial for a new combination bladder cancer therapy highlights a significant advancement in oncology. This breakthrough signals a promising investment opportunity in the broader field of innovative cancer treatments, especially among companies developing combination therapies and targeted drugs.
Published: 19 October 2025
Explore BasketAlternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: 13 October 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: 12 October 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: 11 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage pipeline
A developing pipeline can offer upside if trials succeed, though outcomes are binary and progress can be slow.
Clinical catalysts
Upcoming readouts or regulatory milestones may move the share price significantly, but they also carry meaningful downside risk.
Funding and partners
Partnerships or financing rounds can accelerate programmes but may dilute shareholders; track filings for updates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
